Apollomics Inc. Class A Ordinary Shares (APLM)vsRegeneron Pharmaceuticals Inc (REGN)
APLM
Apollomics Inc. Class A Ordinary Shares
$17.50
-5.91%
HEALTHCARE · Cap: $60.31M
REGN
Regeneron Pharmaceuticals Inc
$951.19
-0.86%
HEALTHCARE · Cap: $95.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 190990% more annual revenue ($16.90B vs $8.84M). REGN leads profitability with a 28.5% profit margin vs -123.7%. REGN earns a higher WallStSmart Score of 78/100 (B+).
APLM
Avoid33
out of 100
Grade: F
REGN
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for APLM.
Margin of Safety
+39.8%
Fair Value
$1500.88
Current Price
$951.19
$549.69 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 431.9%
Revenue surging 380.8% year-over-year
Conservative balance sheet, low leverage
Strong operational efficiency at 40.5%
Revenue surging 36.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1305.0% — below average capital efficiency
Expensive relative to growth rate
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : APLM
The strongest argument for APLM centers on Operating Margin, Revenue Growth, Debt/Equity. Revenue growth of 380.8% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 40.5%. Revenue growth of 36.3% demonstrates continued momentum.
Bear Case : APLM
The primary concerns for APLM are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Piotroski F-Score.
Key Dynamics to Monitor
APLM profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
APLM carries more volatility with a beta of 1.54 — expect wider price swings.
APLM is growing revenue faster at 380.8% — sustainability is the question.
REGN generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
REGN scores higher overall (78/100 vs 33/100), backed by strong 28.5% margins and 36.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apollomics Inc. Class A Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company is headquartered in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?